Loading clinical trials...

Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy? | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

Does Subacromial Injection With Glutamate Receptor (NMDAR) Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

NCT02967640•Helse Møre og Romsdal HF

View on ClinicalTrials.gov

Summary

The hypothesis of the present study is that in patients with rotator cuff tendinopathy a specific pharmacological blocking of peripheral glutamate-receptor N-methyl-d-aspartate receptor type1 (NMDAR) glutamate receptors will result in pain alleviation. Activated NMDAR1 has been demonstrated to be crucial for pain regulation in various pain disorders, and in biopsies from patients with tendinopathy, NMDAR1 was found to be activated. To test this hypothesis a specific NMDA receptor antagonist, ketalar (ketamine), will be injected guided by ultrasound into the subacromial space in patients with rotator cuff tendinopathy, and subsequently the pain response will be assessed.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•diagnosis of rotator cuff tendinopathy by exercise-related shoulder pain with positive impingement tests as described by Hawkins and Neers, and MRI findings consistent with tendinopathy.
•Symptom duration at least 1 year to ensure neuronal ingrowth and NMDAR expression

Exclusion Criteria

•previous surgery in any shoulder.
•previous cortisone use, either as injections or orally
•symptoms or signs of cervicobrachialgia or polyneuropathy
•full thickness rotator cuff ruptures verified by MRI
•primary inflammatory mediated pain, hence, patients with glenohumeral arthrosis, glenohumeral arthritis or systemic disorders predisposing for arthritis
•a central component of pain perception manifested by radiating pain in the involved limb; implying worse outcome after subacromial decompression.
•pregnancy
•breastfeeding
•reduced liver function (Increased serum bilirubin, ASAT or ALAT), decompensated heart failure (NYHA class 3-4)
•increased intracranial pressure or disease of the central nervous system (CNS)
+14 more criteria

Locations (1)

Department of Orthopedic Surgery, Kristiansund Hospital

Kristiansund, Norway

Key Dates

Start Date

May 30, 2018

Primary Completion Date

December 30, 2024

Completion Date

December 30, 2024

Last Updated

August 22, 2025

Enrollment

ACTUAL participants

Conditions

Rotator Cuff TendinitisChronic Pain

Interventions

Ketalar

DRUG

NaCl 9%

DRUG

Optimization of NIBS for Treatment of Addiction

NCT04379115

Opioid-use DisorderChronic Pain

View study

RECRUITINGNA

VR Mindfulness Training for Veterans With SCI

NCT06587607

Spinal Cord InjuryChronic Pain

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

Inclusion Criteria

Exclusion Criteria

Optimization of NIBS for Treatment of Addiction

VR Mindfulness Training for Veterans With SCI

CIH Stepped Care for Co-occurring Chronic Pain and PTSD

Personalized High-Definition tDCS Protocols for Chronic Pain Treatment

Osteopathic Manual Therapy vs Ganglion Impar Block for Chronic Coccydynia

A Mobile Intervention to Reduce Pain and Improve Health-III